JP2009528375A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528375A5
JP2009528375A5 JP2008557453A JP2008557453A JP2009528375A5 JP 2009528375 A5 JP2009528375 A5 JP 2009528375A5 JP 2008557453 A JP2008557453 A JP 2008557453A JP 2008557453 A JP2008557453 A JP 2008557453A JP 2009528375 A5 JP2009528375 A5 JP 2009528375A5
Authority
JP
Japan
Prior art keywords
compound
carbon atoms
hydrogen
hydroxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008557453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/062574 external-priority patent/WO2007101060A2/en
Publication of JP2009528375A publication Critical patent/JP2009528375A/ja
Publication of JP2009528375A5 publication Critical patent/JP2009528375A5/ja
Pending legal-status Critical Current

Links

JP2008557453A 2006-02-28 2007-02-22 代謝障害を処置するための化合物 Pending JP2009528375A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77767806P 2006-02-28 2006-02-28
PCT/US2007/062574 WO2007101060A2 (en) 2006-02-28 2007-02-22 Compounds for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009528375A JP2009528375A (ja) 2009-08-06
JP2009528375A5 true JP2009528375A5 (https=) 2011-03-03

Family

ID=38459732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557453A Pending JP2009528375A (ja) 2006-02-28 2007-02-22 代謝障害を処置するための化合物

Country Status (13)

Country Link
US (2) US20100227901A1 (https=)
EP (1) EP1988772B1 (https=)
JP (1) JP2009528375A (https=)
KR (1) KR20080098615A (https=)
CN (1) CN101394738A (https=)
AT (1) ATE530066T1 (https=)
AU (1) AU2007220868B2 (https=)
CA (1) CA2642662A1 (https=)
IL (1) IL193321A0 (https=)
MX (1) MX2008011022A (https=)
NZ (1) NZ570100A (https=)
WO (1) WO2007101060A2 (https=)
ZA (1) ZA200806444B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
JP5496913B2 (ja) * 2008-01-15 2014-05-21 ウェルスタット セラピューティクス コーポレイション 代謝異常の治療のための化合物
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
EP3818988A1 (en) * 2009-11-03 2021-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8500260B2 (en) 2011-04-27 2013-08-06 Xerox Corporation Ink compositions incorporating substituted oxazoline compounds or substituted oxazoline derivatives
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824843A (en) * 1987-06-25 1989-04-25 Warner-Lambert Company Substituted amide inhibitors of cholesterol absorption
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
ES2288957T3 (es) * 2000-05-12 2008-02-01 Ortho-Mcneil Pharmaceutical, Inc. 4h-benzo(1.4)oxazin-3-ina biologicamente activas.
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
CA2502297C (en) * 2002-11-01 2011-12-13 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MXPA05008600A (es) * 2003-02-13 2005-11-04 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
CN1774244A (zh) * 2003-04-15 2006-05-17 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
CN1777576A (zh) * 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
MXPA05011592A (es) * 2003-04-30 2005-12-15 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
DE602004031954D1 (de) * 2003-08-20 2011-05-05 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen

Similar Documents

Publication Publication Date Title
JP2009528375A5 (https=)
JP2009531280A5 (https=)
JP2009528275A5 (https=)
JP2009537559A5 (https=)
CA2513092A1 (en) Compounds for the treatment of metabolic disorders
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
JP2006524252A5 (https=)
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
JP6238460B2 (ja) 脂質異常症治療剤
CA2521589A1 (en) Compounds for the treatment of metabolic disorders
RU2008123000A (ru) Соединения для лечения метаболических нарушений
JP2011519865A5 (https=)
JP2004524312A5 (https=)
JP2009530398A5 (https=)
RU2004105956A (ru) Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п.
RU2010141823A (ru) Соединения и способ снижения мочевой кислоты
CN103102348B (zh) 噁二唑类化合物及其制备方法、药物组合物及其用途
JP2005526696A5 (https=)
JP2009524686A5 (https=)
RU2006108572A (ru) Соединения для лечения метаболических нарушений
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
JP2009528997A5 (https=)
EP1868595B1 (en) Compounds for the treatment of metabolic disorders
EP1569904B1 (en) Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity
NZ569728A (en) Compounds for the treatment of metabolic disorders